CIK 0001093557
- Large accelerated filer
DEXCOM INC
Sign in to watch- Ticker
- DXCM
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330857544
- Phone
- +1 858-200-0200
- Business address
- 6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,328,435
- in 8 filings, $4.3M under 10b5-1 plans
Net −$4,328,435. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- SAYER KEVIN R −$2.4M Executive Chair sold 8% of stake
- AUGUSTINOS NICHOLAS −$680K Director sold 22% of stake
- Stern Sadie −$649K EVP Chief People & Culture Off sold 6% of stake
- Sylvain Jereme M −$303K EVP, Chief Financal Officer sold 2% of stake
- Brown Michael Jon −$288K EVP Chief Legal Compliance Off sold 3% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-29 | Dolan Matthew Vincent EVP, Strategy & Corporate Dev | Sale | −1,183 | $86.91 | $103K | 42,044 |
| 2025-01-28 | Dolan Matthew Vincent EVP, Strategy & Corporate Dev | Grant or award | +3,048 | 43,227 | ||
| 2024-05-15 | Dolan Matthew Vincent EVP Strategy and Corporate Dev | Sale 10b5-1 | −2,423 | $126.58 | $307K | 40,075 |
| 2024-04-15 | Dolan Matthew Vincent EVP Strategy and Corporate Dev | Sale 10b5-1 | −1,990 | $137.81 | $274K | 42,377 |
| 2024-03-15 | Dolan Matthew Vincent EVP Strategy & Corp Dev | Sale 10b5-1 | −1,886 | $129.18 | $244K | 46,684 |
| 2024-03-15 | Dolan Matthew Vincent EVP Strategy & Corp Dev | Sale 10b5-1 | −1,314 | $130.77 | $172K | 45,370 |
| 2024-03-15 | Dolan Matthew Vincent EVP Strategy & Corp Dev | Sale 10b5-1 | −1,003 | $131.39 | $132K | 44,367 |
| 2024-03-12 | Dolan Matthew Vincent EVP Strategy and Corporate | Sale | −6,710 | $134.41 | $902K | 48,570 |
| 2024-03-08 | Dolan Matthew Vincent EVP Strategy and Corporate | Grant or award | +21,711 | 55,280 | ||
| 2023-09-01 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sale | −56 | $102.32 | $6K | 33,569 |
| 2023-03-16 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sale | −2,303 | $115.00 | $265K | 33,569 |
| 2023-03-13 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sale | −6,229 | $106.27 | $662K | 35,872 |
| 2023-03-10 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Returned to the company | −1,370 | $111.40 | $153K | 46,935 |
| 2023-03-10 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Returned to the company | −1,650 | $111.40 | $184K | 45,285 |
| 2023-03-10 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Returned to the company | −2,397 | $111.40 | $267K | 42,888 |
| 2023-03-10 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Returned to the company | −787 | $111.40 | $88K | 42,101 |
| 2023-03-08 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Grant or award | +21,769 | $0.00 | $22 | 48,305 |
| 2023-03-06 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sale | −226 | $114.40 | $26K | 26,536 |
| 2022-09-01 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sale | −5 | $81.63 | $408 | 26,536 |
| 2022-03-17 | Dolan Matthew Vincent SVP Corporate Development | Sale | −484 | $450.00 | $218K | 6,634 |
Page 1 of 2 · 27 trades